中国医学创新2016，Vol.13Issue(31)：94-96,3.DOI:10.3969/j.issn.1674-4985.2016.31.027
多西他赛对老年非小细胞肺癌患者心脏毒性的临床研究
Clinical Study Cardiac Toxicity of Docetaxel for Elderly Patients with Non-small Cell Lung Cancer
摘要
Abstract
Objective:To study the analysis of cardiac toxicity in elderly patients with non-small cell lung cancer for Docetaxel.Method:60 cases of elderly patients with non-small cell lung cancer from September 2014 to September 2015 were selected for this study,they were given Docetaxel 30.0-37.5 mg/m2,intravenous infusion in the first and eighth day,administered every 21 days for 1 cycle,they were treated 3 cycles.Then,they were given the pretreatment and antiemetic therapy.The therapeutic effects of chemotherapy and chemotherapy before were observed,the patients with cardiac toxicity monitoring at the end, after the end of 12,24,48 and 72 h were compared.Result:In 60 cases,11 cases of complete remission, partial remission in 24 cases,14 cases were stable, clinical control the rate for 81.67%. The levels of serum cTnI and C in the serum of before chemotherapy, after chemotherapy, after chemotherapy 12,24,48 and 72h were higher than those before treatment,the difference was statistically significant (P<0.05).There were 9 patients with ECG changes,accounting for 15%, including sinus bradycardia 2 cases(3.33%) sinus,sinus tachycardia in 4 cases(6.67%),2 cases(3.33%) of atrioventricular block,ST-T changes in 1 case(1.67%).72 cases of gradeⅠtoxicity,2 cases of grade Ⅱtoxicity.Conclusion:The combination of Docetaxel for elderly patients with non-small cell lung cancer patients, although there is a better therapeutic effect,but after chemotherapy can cause cardiac toxicity in patients,in clinical drug toxicity should to drugs and strengthen the monitoring and treatment, ensure the safety of the patients.关键词
非小细胞肺癌/老年/多西他赛/心脏毒性Key words
Non small cell lung cancer/Elderly/Docetaxel/Cardiac toxicity引用本文复制引用
周正宇,张静,邱宇安,管湘霞,姜桂香,刘龙燕..多西他赛对老年非小细胞肺癌患者心脏毒性的临床研究[J].中国医学创新,2016,13(31):94-96,3.基金项目
江西省卫生厅科技计划项目 （）
